Find a Physician | How to Contribute | Contact Us | Clinical Trials
Search: 
Select a Cancer Type:

Associate Director, Translational Research and Developmental Therapeutics - Francis J. Giles, MD, MB, FRCPI, FRCPath

The Associate Director for Translational Research and Developmental Therapeutics is appointed by and reports to the Director of the Lurie Cancer Center. The primary responsibility of this position is to build intersections with laboratory and clinical research programs to facilitate the translation of basic research discoveries with the intent of advancing therapies to the clinic. To that end, the Associate Director works closely with the entire Senior Leadership team and Program Leaders to promote new translational research funding initiatives, develop research working groups in targeted areas to promote new grant initiatives in translational research, organize an annual translational research retreat to stimulate new collaborations and interactions, organize two translational cancer research mini-symposia per year, and identify investigator needs for shared facility or other infrastructure needs to support translational research. The Associate Director also oversees the competitive award process for intramural funds to promote translational research. The Associate Director serves on the Executive Committee and Leadership Group, playing a critical role in establishing the strategic direction, policy and priorities of the Lurie Cancer Center.

Francis J. Giles, MD, MB, FRCPI, FRCPath is Professor of Medicine at Northwestern University Feinberg School of Medicine and Director of the Northwestern Medicine Developmental Therapeutics Institute. A cancer specialist with more than two decades of experience, Dr. Giles has led the development of novel drugs, immunotherapies, and other highly targeted approaches, including cancer-directed viruses, monoclonal antibodies, and molecularly directed agents. He has served as principal investigator on numerous national and international First in Human, Phase I, II, and III clinical studies of many novel agents, and holds numerous patents and technology licenses. Dr. Giles has focused his clinical and research efforts on providing therapy for patients suffering from treatment-resistant or refractory cancer. He has pioneered the use of many agents that are now in regular use as targeted therapies for patients with cancer. Among his many accolades, Dr. Giles was recently elected as a Fellow of the European Academy of Cancer Sciences. Dr. Giles has particular interests in the mentoring of developmental therapeutics physician-scientists and in international collaborations across the bioscience spectrum.